In this study, we show that gliotoxin as a nuclear NOTCH2 inhibitor may have an additional therapeutic advantage over GSI as pan-NOTCH inhibitors in CLL. The gene discussed is NOTCH2; the disease is B-cell chronic lymphocytic leukemia.